Sign In
Buy ADIL
$2.71
+0.110 (+4.23%)
At Close: Jun 22, 2026
Maxim Group Remains a Buy on Adial Pharmaceuticals (ADIL) - Markets
06:45pm, Friday, 31'st Jul 2020
Maxim Group analyst Jason McCarthy reiterated a Buy rating on Adial Pharmaceuticals (ADIL – Research Report) yesterday and set a
Adial Pharmaceuticals Schedules Business and Clinical Update Conference Call
01:30pm, Tuesday, 28'th Jul 2020
Developments to be Shared by Dr.
EMA Agreement paves the way for a marketing authorization in Europe after Phase 3CHARLOTTESVILLE, VA / ACCESSWIRE / July 22, 2020 / Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia
12:15pm, Monday, 06'th Jul 2020
CHARLOTTESVILLE, VA / ACCESSWIRE / July 6, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL:ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for add
Today's Exchange Rate News 26.06.2020: Pound Tracks Sideways, Euro Weak, Dollar Steady As US Statistics Mixed
07:00am, Friday, 26'th Jun 2020
Today's Exchange Rate News 26.06.2020: Pound Tracks Sideways, Euro Weak, Dollar Steady as US Statistics Mixed
Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland | | IT Business Net
03:11pm, Thursday, 25'th Jun 2020
Polish clinical sites initiated less than two weeks after regulatory approval CHARLOTTESVILLE, VA / ACCESSWIRE / June 25, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a
Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland
01:30pm, Thursday, 25'th Jun 2020
CHARLOTTESVILLE, VA / ACCESSWIRE / June 25, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for a
Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia | | IT Business Net
03:11pm, Wednesday, 17'th Jun 2020
ONWARD™ trial progresses with the opening of sites in Latvia CHARLOTTESVILLE, VA / ACCESSWIRE / June 17, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage b
Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia
01:55pm, Wednesday, 17'th Jun 2020
CHARLOTTESVILLE, VA / ACCESSWIRE / June 17, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for a
AUD/USD reversal extends to 0.6833 lows against a firmer US dollar | Forex Crunch
02:27pm, Tuesday, 16'th Jun 2020
AUD/USD reversal from 0.6975 extends to intra-day lows at 0.6833. The US dollar loses appreciates with equity markets off highs as market mood sours.
Adial Pharmaceuticals Closes Previously Announced $5.2 Million Registered Direct Offering | | IT Business Net
03:11pm, Monday, 15'th Jun 2020
CHARLOTTESVILLE, VA / ACCESSWIRE / June 15, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a biopharmaceutical company focused on the developme
Adial Pharmaceuticals Closes Previously Announced $5.2 Million Registered Direct Offering
01:30pm, Monday, 15'th Jun 2020
CHARLOTTESVILLE, VA / ACCESSWIRE / June 15, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a biopharmaceutical company focused on the development of treatments for
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland
03:35pm, Thursday, 11'th Jun 2020
CHARLOTTESVILLE, VA / ACCESSWIRE / June 11, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for a
Adial Pharmaceuticals Receives Order for 1,000 COVID-19 Antibody Test Kits
02:06pm, Wednesday, 10'th Jun 2020
CHARLOTTESVILLE, VA / ACCESSWIRE / June 10, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for a
Adial Pharmaceuticals Announces Pricing of $5.2 Million Registered Direct Offering Priced At-The-Market
01:15pm, Tuesday, 09'th Jun 2020
CHARLOTTESVILLE, VA / ACCESSWIRE / June 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a biopharmaceutical company focused on the development of treatments for
